Podcast 729: Molnupiravir for COVID

Contributor: Jared Scott, MD

Educational Pearls:

• A press release from Merck introduced Molnupiravir for treatment of mild to moderate COVID-19
• The yet to be published study is a randomized control trial at around 100 different sites
• Reported outcomes were hospitalization and mortality from COVID and mortality from COVID
• Molnupiravir was found to be twice as effective as placebo looking at these two endpoints (7% vs. 14%)
• 5 day course of the drug taken twice per day costs $700, but cost-saved from using this drug was $32,000 per patient

References

https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/

https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-oral-covid-19-antiviral-medicine-receives-first-authorization-in-the-world/

Summarized by John Spartz, MS4 | Edited by Erik Verzemnieks, MD

The Emergency Medical Minute is excited to announce that we are now offering AMA PRA Category 1 credits™ via online course modules. To access these and for more information, visit our website at https://emergencymedicalminute.org/cme-courses/ and create an account. 

Donate to EMM today!

Diversity and Inclusion Award